Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: Preliminary results of the Hungarian multicentric prospective randomised study;In situ duktális emlokarcinóma kombinált sebészi- és sugárkezelése: a magyarországi multicentrikus prospektív randomizált vizsgálat korai eredményei

Magyar Onkologia

Volumn 52, Issue 3, 2008, Pages 269-277

  Polgár, Csaba ^a   Orosz, Zsolt ^b   Kahán, Zsuzsanna ^c   Gábor, Gabriella ^b   Jani, Nóra ^b   Cserni, Gábor ^b   Hadev, Janaki ^b   Kulka, Janina ^d   Sulyok, Zoltán ^b   Boross, Gábor ^e   Lázár, György ^f   László, Zsolt ^g   Diczházi, Csaba ^h   Nóra, Udvarhelyi ^b   Szabó, Éva ⁱ   Zoltán, Péntek ^g   Major, Tibor ^a   Fodor, János ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b Daganatpatológiai ^*  (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d II Sz Patológiai Intézet   (Hungary)

^e Bács Kiskun Megyei Onkormányzat Kórháza   (Hungary)

^f UNIVERSITY OF SZEGED   (Hungary)

^g MaMMa Egészségügyi Zrt   (Hungary)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ Radiológiai Diagnosztikai Osztály   (Hungary)

Author keywords

Breast ductal carcinoma in situ; Breast conserving surgery; Local recurrence; Molecular prognostic markers; Radiotherapy; Randomised clinical study

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUNGARY; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; RISK FACTOR; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; HUNGARY; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REOPERATION; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149265475     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: 10.1556/MOnkol.52.2008.3.4     Document Type: Article

References (59)

1. Adlard JW, Bundredt NJ. Radiotherapy for ductal carcinoma in situ. Clin Oncol (R Coll Radiol) 18:179-184, 2006
2. Amichetti M, Caffo O, Richetti A, et al. Subclinical ductal carcinoma in situ of the breast: treatment with conservative surgery and radiotherapy. Tumori 85:488-493, 1999
3. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25:3259-3265, 2007
4. Bffker N, Meffnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381-3387, 2006
5. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-Analysis. Cancer 85:616-628, 1998
6. Consensus Conference Committee. Consensus Conference on the Classification of Ductal Carcinoma in Situ, April 25-28, 1997. Cancer 80:1798-1802, 1997
7. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast-A study of a large cohort of patients treated with surgery alone. Cancer 100:2317-2327, 2004
8. Cuzick J. Treatment for DCIS-results from clinical trials. Surg Oncol 12:213-219, 2003
9. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087-2106, 2005
10. Emdin SO, Granstrand B, Ringberg A, et al. DCIS: Radiotherapy aft er sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45:536-543, 2006
11. Fietkau R. Ductal carcinoma in situ of the breast: Increasing importance of radiotherapy as a part of the therapy approach. Strahlenther Onkol 180:682-689, 2004
12. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med 347:1233-1241, 2002
13. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. New Engl J Med 328:1581-1586, 1993
14. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
15. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28:400-418, 2001
16. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: Intraductal carcinoma. Cancer 86:429-438, 1999
17. Fodor J, Major T, Polgár Cs, et al. Az emlrák lokális kiújulása emlmegtartó mtét után: a sugárterápia értékelése. Magyar Onkológia 42:225-228, 1998
18. Fodor J, Polgár Cs, Németh G. Az operábilis emlrák bizonyítékokon alapuló sugá rkezelése: a 90-es évek eredményeinek elemzése. Orvosi Hetilap 28:1551-1555, 2000
19. Hieken TJ, Farolan M, D'Alessandro S, et al. Predicting the biologic behaviour of ductal carcinoma in situ: An analysis of molecular markers. Surgery 130:593-601, 2001
20. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95-102, 2003
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challanges. J Natl Cancer Inst 96:906-920, 2004
23. MacAusland SG, Hepel JT, Chong FK, et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110:2648-2653, 2007
24. Macdonald HR, Silverstein MJ, Lee LA, et al. Margin width as the sole determinant of local recurrence aft er breast conservation in patients with ductal carcinoma in situ of the breast. Am J Surg 192:420-422, 2006
25. Mascarel I, Bonichon F, MacGrogan G, et al: Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: Practical considerations. Breast Cancer Res Treat 61:151-159, 2000
26. Meffnen P, Peterse JL, Antonini N, et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 98:137-142, 2008
27. Mokbel K: Contemporary treatment of ductal carcinoma in situ of the breast. Med Sci Monit 11:86-93, 2005
28. Mokbel K, Cutuli B. Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol 7:756-765, 2006
29. Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 7:652-656, 2006
30. Orosz Zs, Jani N, Kahán Zs, et al. In situ ductalis emlcarcinomák (DCIS) multicentrikus klinikopatológiai elemzése. Magyar Onkológia 51:376, 2007
31. Perin T, Canzonieri V, Massarut S, et al. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 32A:1148-1155, 1996
32. Polgár C, Fodor J, Major T, et al. The role of boost irradiation in the conservative treatment of stage I-II breast cancer. Pathol Oncol Res 7:241-250, 2001
33. Polgár C, Fodor J, Orosz Z, et al. Electron and brachytherapy boost in the conservative treatment of stage I-II breast cancer: 5-year results of the randomized Budapest boost trial. Radiother Oncol 64(Suppl 1): S15, 2002
34. Polgár C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma-5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 69:694-702, 2007
35. Polgár Cs, Fodor J, Németh Gy. A korai emlrák sugárkezelése: Több mint loko-regionális daganatkontroll. Magyar Onkológia 45:361-371, 2001
36. Polgár Cs, Fodor J, Orosz Zs, et al. A tumorágy kiegészít besugárzásának hatása a lokális daganatmentességre emlmegtartó mtét után: Az Országos Onkológiai Intézet randomizált boost" vizsgálatának els eredményei. Magyar Onkológia 45:385-391, 2001
37. Polgár C, Strnad V, Major T. Brachytherapy for partial breast irradiation: The European experience. Semin Radiat Oncol 15:116-122, 2005
38. Provenzano E, Hopper JL, Giles GG, et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39:622-630, 2003
39. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 16:2018-2024, 1998
40. Rajan PB, Scott DJ, Perry RH, et al. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 42:283-290, 1997
41. Ringberg A, Anagnostaki L, Anderson H, et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37:1514-1522, 2001
42. Ringberg A, Idvall I, Fernö M, et al. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur J Surg Oncol 26:444-451, 2000
43. Ringberg A, Nordgren H, Thorstensson S, et al. Histopathological risk factors for ipsilateral breast events aft er breast conserving treatment for ductal carcinoma in situ of the breast-Results from the Swedish randomised trial. Eur J Cancer 43:291-298, 2007
44. Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963-968, 1997
45. Schnitt SJ, Harris JR, Smith BL. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet? Cancer 77:2189-2192, 1996
46. Schwartz GF, Solin LJ, Olivotto IA, et al. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. Cancer 88:946-954, 2000
47. Silverstein MJ. The University of Southern California/Van Nuys Prognostic Index. In: Ductal carcinoma in situ of the breast. Ed. Silverstein MJ. Lippincott Williams & Wilkins, Philadelphia, USA 2002, pp 459-473
48. Silverstein MJ. The Van Nuys/University of Southern California experience by treatment. In: Ductal carcinoma in situ of the breast. Ed. Silverstein MJ. Lippincott Williams & Wilkins, Philadelphia, USA 2002, pp 337-342
49. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267-2274, 1996
50. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455-1461, 1999
51. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154-1157, 1995
52. Sumner WE, Koniaris LG, Snell SE, et al. Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol 14:1638-1643, 2007
53. Vargas C, Kestin L, Go N, et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys 63:1514-1521, 2005
54. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year followup of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New Engl J Med 347:1227-1232, 2002
55. Viani GA, Stefano EJ, Afonso SL, et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-Analysis of randomized trials. Rad Oncol 2:28, 2007
56. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24:1031-1036, 2006
57. Zagouri F, Sergentanis TN, Zografos GC. Precursors and preinvasive lesions of the breast: the role of molecular prognostic factors in the diagnostic and therapeutic dilemma. World J Surg Oncol 5:58, 2007
58. Zaugg K, Bodis S. Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast? Radiother Oncol 55:85-99, 2000
59. Zhang Z, Yamashita H, Toyama T, et al: Semi-quantitative immuno-histochemical analysis of aromatase expression in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 74:47-53, 2002